Positive results from GENESIS Phase III trial of motixafortide in stem-cell mobilization for autologous bone marrow transplantation in multiple myeloma .BioLineRx Ltd
BioLineRx Ltd. announced positive top-line results from the Company's GENESIS Phase III trial evaluating its lead clinical candidate, motixafortide, in combination with granulocyte colony stimulating factor (G-CSF, the standard of care in this indication), for hematopoietic stem-cell mobilization for autologous bone marrow transplantation in multiple myeloma patients.